A MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP PILOT STUDY TO EVALUARTE SAFETY AND EFFICACY OF CONVALESCENT METHYLENE BLUE TREATED (MBT) PLASMA FROM DONORS RECOVERED FROM CORONAVIRUS DISIASE 2019 (COVID-19) WITH STANDARD MEDICAL TREATMENT (SMT) VERSUS SMT ALONE IN SUBJECTS WITH COVID-19 REQUIRING